Avoid Ferumoxytol in the First Trimester—Defer Until After 13 Weeks Gestation
Do not administer ferumoxytol (Feraheme) in the first trimester of pregnancy. The most recent expert consensus guidelines explicitly recommend avoiding IV iron prior to 13 weeks gestation 1, and the FDA drug label warns of fetal malformations and decreased fetal weights observed in animal studies during organogenesis 2.
Key Clinical Reasoning
Guideline-Based Timing Restriction
The 2024 expert consensus guidelines from the American Journal of Hematology provide clear direction: avoid IV iron prior to 13 weeks gestation 1. This recommendation takes precedence over the severity of iron deficiency, even with a critically low ferritin of 4 ng/mL.
FDA Safety Concerns
The Feraheme drug label categorizes pregnancy data as having "limited available data" that are "insufficient to inform a drug-associated risk" 2. Critical safety signals include:
- Animal teratogenicity: Ferumoxytol caused fetal malformations and decreased fetal weights in rabbits at 6 times the human dose during organogenesis 2
- Severe maternal reactions: Hypotension, shock, and anaphylactic reactions can cause fetal bradycardia, particularly concerning during second and third trimesters 2
- First trimester vulnerability: Organogenesis occurs during weeks 3-13, making this the highest-risk period for teratogenic exposures
Management Algorithm for This Patient
Immediate Actions (First Trimester)
- Initiate oral iron therapy: Start ferrous sulfate 325 mg twice daily despite known GI side effects
- Nutritional counseling: Optimize dietary iron intake and vitamin C co-administration
- Monitor closely: Recheck hemoglobin and ferritin every 2-4 weeks
- Document gestational age precisely: Confirm dating to plan IV iron timing
After 13 Weeks Gestation
Once the patient reaches the second trimester (≥13 weeks):
- Administer ferumoxytol 1020 mg (two 510 mg vials) in 100 mL normal saline infused over 30 minutes 1
- This single-dose approach is supported by recent evidence showing superior efficacy compared to oral iron (mean hemoglobin increase of 1.86 g/dL vs 0.79 g/dL) 3
- Ferumoxytol has been studied in 131 consecutive pregnant women in second and third trimesters with no adverse events reported 4
Important Caveats
Severity Does Not Override Timing
While a ferritin of 4 ng/mL represents severe iron deficiency, the teratogenic risk during organogenesis outweighs the maternal benefit of rapid iron repletion. Untreated IDA does carry risks (preterm delivery, low birthweight) 2, but these are primarily associated with persistent anemia later in pregnancy, not first-trimester iron deficiency per se.
Alternative Considerations
If the patient cannot tolerate oral iron and hemoglobin drops to transfusion-requiring levels (<7 g/dL with symptoms), red blood cell transfusion would be safer than first-trimester IV iron.
Post-13 Week Advantages of Ferumoxytol
Once timing permits, ferumoxytol offers significant advantages over iron sucrose (the traditional obstetric standard):
- Single visit vs 4-7 visits for complete repletion 4
- Comparable safety profile to other IV iron formulations 5
- Superior efficacy to oral iron with better tolerability 3
The evidence consistently supports deferring IV iron until after the first trimester while managing with oral supplementation, then using ferumoxytol as an efficient, safe option for rapid iron repletion in the second and third trimesters 1, 2, 3, 4.